Corcept Therapeutics (NASDAQ:CORT) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS

Corcept Therapeutics (NASDAQ:CORT) posted its earnings results on Tuesday. The biotechnology company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.22, FiscalAI reports. The business had revenue of $340.47 million for the quarter, compared to analyst estimates of $336.37 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. Corcept Therapeutics’s revenue was up 64.0% compared to the same quarter last year. During the same period last year, the business posted $0.16 EPS.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Third-quarter revenue rose 64% year over year to $340.5 million, while net income increased to $126.8 million and cash and investments reached $662 million. Management reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion.
• Lifyorli revenue climbed 92% sequentially to $91.4 million, with more than 2,300 patients treated since launch and increasing repeat prescribing. Management believes the drug can become the market-share leader in platinum-resistant ovarian cancer and generate more than $1 billion in annual revenue.
• Corcept expects broader screening recommendations for hypercortisolism to expand its endocrinology market, forecasting at least $2 billion in annual Cushing’s syndrome revenue by the end of the decade, potentially reaching $3 billion to $5 billion in 2030 with relacorilant.
• The FDA is reviewing relacorilant’s resubmitted Cushing’s syndrome application, with a December 17 PDUFA date; management provided no additional regulatory detail. The company also plans additional studies in oncology, MASH, and ALS, with several results expected by the end of next year.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $81.93 on Wednesday. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $126.38. The stock has a market cap of $8.86 billion, a PE ratio of 195.08 and a beta of 0.54. The firm has a 50-day simple moving average of $110.31 and a 200 day simple moving average of $75.06.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 64% year over year to $340.5 million, topping analyst expectations of about $336.4 million. Earnings of $1.01 per share also exceeded the $0.79 consensus estimate, with EPS sharply higher than the $0.16 reported a year earlier. Quarterly earnings report
• Positive Sentiment: Corcept said it is targeting $3 billion to $5 billion in Cushing’s syndrome revenue by 2030, signaling substantial long-term growth ambitions. Cushing’s revenue target and FDA update
• Neutral Sentiment: The FDA is expected to decide on relacorilant on December 17. A decision could be an important catalyst, but the outcome and commercial impact remain uncertain. Relacorilant FDA decision update
• Negative Sentiment: Shares came under pressure despite the earnings beat, with reports attributing the reaction to disappointing guidance. That suggests investors are concerned that the forward outlook may not match the strong recent results. Report on guidance and investor reaction

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. HC Wainwright reissued a “buy” rating and set a $165.00 price objective on shares of Corcept Therapeutics in a research report on Friday, September 18th. Piper Sandler restated an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, Truist Financial started coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Corcept Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $138.17.

Insider Activity

In other Corcept Therapeutics news, insider Roberto Vieira sold 58,333 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total value of $6,460,963.08. Following the completion of the sale, the insider owned 4,242 shares in the company, valued at approximately $469,843.92. This trade represents a 93.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David L. Mahoney sold 103,606 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $118.25, for a total value of $12,251,409.50. Following the sale, the director directly owned 1,133,539 shares in the company, valued at $134,040,986.75. The trade was a 8.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 349,203 shares of company stock valued at $40,686,076. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.